186 related articles for article (PubMed ID: 21986283)
1. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial.
Calhoun DA; White WB; Krum H; Guo W; Bermann G; Trapani A; Lefkowitz MP; Ménard J
Circulation; 2011 Nov; 124(18):1945-55. PubMed ID: 21986283
[TBL] [Abstract][Full Text] [Related]
2. Sequential comparison of aldosterone synthase inhibition and mineralocorticoid blockade in patients with primary aldosteronism.
Amar L; Azizi M; Menard J; Peyrard S; Plouin PF
J Hypertens; 2013 Mar; 31(3):624-9; discussion 629. PubMed ID: 23314743
[TBL] [Abstract][Full Text] [Related]
3. Aldosterone synthase inhibition in humans.
Azizi M; Amar L; Menard J
Nephrol Dial Transplant; 2013 Jan; 28(1):36-43. PubMed ID: 23045428
[TBL] [Abstract][Full Text] [Related]
4. Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects.
Ménard J; Rigel DF; Watson C; Jeng AY; Fu F; Beil M; Liu J; Chen W; Hu CW; Leung-Chu J; LaSala D; Liang G; Rebello S; Zhang Y; Dole WP
J Transl Med; 2014 Dec; 12():340. PubMed ID: 25491597
[TBL] [Abstract][Full Text] [Related]
5. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism.
Amar L; Azizi M; Menard J; Peyrard S; Watson C; Plouin PF
Hypertension; 2010 Nov; 56(5):831-8. PubMed ID: 20837883
[TBL] [Abstract][Full Text] [Related]
6. Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension.
Karns AD; Bral JM; Hartman D; Peppard T; Schumacher C
J Clin Hypertens (Greenwich); 2013 Mar; 15(3):186-92. PubMed ID: 23458591
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.
Lee H; Yang HM; Lee HY; Kim JJ; Choi DJ; Seung KB; Jeon ES; Ha JW; Rim SJ; Park JB; Shin JH; Oh BH
Clin Ther; 2012 Jun; 34(6):1273-89. PubMed ID: 22608107
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension.
White WB; Carr AA; Krause S; Jordan R; Roniker B; Oigman W
Am J Cardiol; 2003 Jul; 92(1):38-42. PubMed ID: 12842242
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.
Germino FW
Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484
[TBL] [Abstract][Full Text] [Related]
10. The effects of aldosterone synthase inhibition on aldosterone and cortisol in patients with hypertension: a phase II, randomized, double-blind, placebo-controlled, multicenter study.
Andersen K; Hartman D; Peppard T; Hermann D; Van Ess P; Lefkowitz M; Trapani A
J Clin Hypertens (Greenwich); 2012 Sep; 14(9):580-7. PubMed ID: 22947355
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of dual ACE/NEP inhibitor GW660511X in mild-to-moderate hypertensive patients.
Johnson AG; Pearce GL; Danoff TM
J Hum Hypertens; 2006 Jul; 20(7):496-503. PubMed ID: 16543907
[TBL] [Abstract][Full Text] [Related]
12. Effects of eplerenone versus losartan in patients with low-renin hypertension.
Weinberger MH; White WB; Ruilope LM; MacDonald TM; Davidson RC; Roniker B; Patrick JL; Krause SL
Am Heart J; 2005 Sep; 150(3):426-33. PubMed ID: 16169319
[TBL] [Abstract][Full Text] [Related]
13. The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio.
Hood SJ; Taylor KP; Ashby MJ; Brown MJ
Circulation; 2007 Jul; 116(3):268-75. PubMed ID: 17606839
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study.
Li JS; Flynn JT; Portman R; Davis I; Ogawa M; Shi H; Pressler ML
J Pediatr; 2010 Aug; 157(2):282-7. PubMed ID: 20400095
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of LCI699 for hypertension: a meta-analysis of randomized controlled trials and systematic review.
Wang HZ; Tian JB; Yang KH
Eur Rev Med Pharmacol Sci; 2015; 19(2):296-304. PubMed ID: 25683946
[TBL] [Abstract][Full Text] [Related]
16. Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial.
Laffin LJ; Rodman D; Luther JM; Vaidya A; Weir MR; Rajicic N; Slingsby BT; Nissen SE;
JAMA; 2023 Sep; 330(12):1140-1150. PubMed ID: 37690061
[TBL] [Abstract][Full Text] [Related]
17. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the dose--response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension.
Puig JG; Schunkert H; Taylor AA; Boye S; Jin J; Keefe DL
Clin Ther; 2009 Dec; 31(12):2839-50. PubMed ID: 20110023
[TBL] [Abstract][Full Text] [Related]
19. Twenty-four hour blood pressure effect of once-daily lisinopril, enalapril, and placebo in patients with mild to moderate hypertension.
Whelton A; Dunne B; Glazer N; Kostis JB; Miller WE; Rector DJ; Tresznewsky ON
J Hum Hypertens; 1992 Aug; 6(4):325-31. PubMed ID: 1331444
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
